Replies to post #368930 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

DAS ENDE???

Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies.
Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow:
Drug Appears Safe and Well Tolerated.
Overall ADAS-Cog11 Scores Improved an Average of 1.5 Points (S.D. ± 6.6; P<0.05)
63% of the 100 Patients Showed an Improvement in ADAS-Cog11 Scores, and This Group of Patients Improved an Average of 5.6 Points (S.D. ± 3.8).
An Additional 21% of the 100 Patients Declined Less Than 5 Points on ADAS-Cog11, and This Group of Patients Declined an Average of 2.7 Points (S.D. ± 1.4).

[frrol]

Those results look better in several ways than our smaller AD phase 2A open label data at 12 months. But it's OL and not very reliable. Cassava's drug may be therapeutic for a large subset of AD patients, but the company is not studying potential genetic and biomic determinants as hard as we are.

Pumping and bashing do not help one's biotech investment. Stay rational and objective, and watch for what matters. Most folks finally understand now what that is.

[Ortiz]

WTF is this? S.D. ± 6.6; P<0.05?

Nice standard deviation, which negates the result. Amazing

IMO